Cardiac Wire #114 September 14, 2023
Lorundrostat Safe and Effective | Private Equity Concerns
Cardiac Wire #113 September 11, 2023
Long-Lasting Blood Pressure Control | Teen ECG Screening
Cardiac Wire #112 September 7, 2023
The State of Cardiology AI | Another Weight Loss Acquisition
Cardiac Wire #111 August 31, 2023
Hold the Anticoagulants with AHREs | ESC 2023
Cardiac Wire #110 August 28, 2023
ReCor Takes RDN Lead | Semaglutide’s HF Impact
Cardiac Wire #109 August 24, 2023
Multimarker Blood Testing | Mouth Rinse CVD Testing
Cardiac Wire #108 August 21, 2023
HF’s Guideline Barrier | Less is More for Home BP
Cardiac Wire #107 August 17, 2023
Pre-EP Lab Questions | ABIM Pressure Intensifies
Cardiac Wire #106 August 14, 2023
Novo Nordisk Expands Weight Loss Pipeline | Beta-Blocker Warning
Cardiac Wire #105 August 10, 2023
Wegovy’s CV Event Impact | Expanding Troponin to CAD
Cardiac Wire #104 August 7, 2023
Novartis and Ionis’s Lp(a) Alliance | What CCTA Misses
Cardiac Wire #103 August 3, 2023
Hims’ CVD Expansion | Cleerly’s 10-Year Predictions
Cardiac Wire #102 July 31, 2023
Tirzepatide’s Weight Loss Superiority | HeartFlow’s All-In-One Results
Cardiac Wire #101 July 27, 2023
Alnylam and Roche’s BP Alliance | ATTR-CM Progress and Promise
Cardiac Wire #100 July 24, 2023
Zilebesiran’s Long-Lasting BP Control | The Rise of Cardiology Private Equity
Cardiac Wire #99 July 20, 2023
Astellas’ Heart Failure DTx Solution | Heart Drugs Medicare Impact
Cardiac Wire #98 July 17, 2023
Lilly Diversifies Weight Loss Pipeline | CMS’ CAS Expansion Proposal
Cardiac Wire #97 July 13, 2023
Cholesterol Control Falls Short | Leqvio’s Primary Expansion
Cardiac Wire #96 July 10, 2023
